Advanced Ovarian Cancer. Malignant neoplasm of ovary
Conditions
Interventions
All patients give three neoadjuant courses and undergo interval debulking surgery. Each course consists of weekly paclitaxel (80mg/m2) and carboplatin (AUC 6) each three weeks. Then, patients in St II
Treatment - Drugs
Sponsors
Taleghani Hospital- Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age over 18yr; Ovarian cancer confirmed by biopsy and pathology; Advanced disease confirmed by CT scan (Stage III or IV); No previous history of chemotherapy; Good liver and lung functional status; No candidate for primary surgery due to underlying disease; Full access to patients medical documents; Patient satisfaction for study participation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS). Timepoint: At the end of followup study. Method of measurement: Cancer free duration after end of tratment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anemia. Timepoint: After each 21 day treatment course. Method of measurement: CBC.;Neutropenia. Timepoint: After each 21 day treatment course. Method of measurement: CBC.;Trombocytopenia. Timepoint: After each 21 day treatment course. Method of measurement: CBC.;Neuropathy. Timepoint: After each 21 day treatment course. Method of measurement: Clinical Exam. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Shirin Haghighi
Taleghani Hospital- Shahid Beheshti University of Medical Sciences
Outcome results
None listed